Loading...
Loading...
EFTR| Name | Value |
|---|---|
| Revenues | 0.0K |
| Cost of Revenue | 0.0K |
| Gross Profit | 0.0K |
| Operating Expense | 8,723.0K |
| Operating I/L | -8,723.0K |
| Other Income/Expense | -538.0K |
| Interest Income | 209.0K |
| Pretax | -9,261.0K |
| Income Tax Expense | 537.0K |
| Net Income/Loss | -9,798.0K |
eFFECTOR Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in the development of selective translation regulator inhibitors for cancer treatment. Its lead product, Tomivosertib, is an oral small-molecule inhibitor of MNK in phase 2b clinical trial for metastatic non-small cell lung cancer. The company is also developing Zotatifin, a small molecule designed to inhibit eukaryotic initiation factor 4A (eIF4E), currently in phase 2 clinical trial for solid tumors. Additionally, eFFECTOR has a collaboration agreement with Pfizer Inc. to develop inhibitors of eIF4E, showcasing its potential for revenue generation through the development and commercialization of innovative cancer therapies.
